Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PTC THERAPEUTICS, INC. Director's Dealing 2020

Oct 8, 2020

31046_dirs_2020-10-07_0ddfb322-8f27-40ed-918d-c4efa608795e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2020-10-05

Reporting Person: Peltz Stuart Walter (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-10-05 Common Stock M 900 $10.85 Acquired 56985 Direct
2020-10-05 Common Stock S 900 $50.00 Disposed 56085 Direct
2020-10-05 Common Stock M 54560 $10.85 Acquired 110645 Direct
2020-10-05 Common Stock S 54560 $50.00 Disposed 56085 Direct
2020-10-06 Common Stock M 50015 $10.85 Acquired 106100 Direct
2020-10-06 Common Stock S 50015 $50.102 Disposed 56085 Direct
2020-10-06 Common Stock M 22511 $10.85 Acquired 78596 Direct
2020-10-06 Common Stock S 22511 $50.148 Disposed 56085 Direct
2020-10-06 Common Stock M 51825 $11.23 Acquired 107910 Direct
2020-10-06 Common Stock S 51825 $50.137 Disposed 56085 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-10-05 Stock Option (Right To Buy) $10.85 M 900 Disposed 2023-05-15 Common Stock (900) Direct
2020-10-05 Stock Option (Right To Buy) $10.85 M 54560 Disposed 2023-05-15 Common Stock (54560) Direct
2020-10-06 Stock Option (Right to Buy) $10.85 M 50015 Disposed 2023-05-15 Common Stock (50015) Direct
2020-10-06 Stock Option (Right to Buy) $10.85 M 22511 Disposed 2023-05-15 Common Stock (22511) Direct
2020-10-06 Stock Option (Right To Buy) $11.23 M 51825 Disposed 2027-01-02 Common Stock (51825) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right To Buy) $490.8 2021-04-27 Common Stock (541.0) 541 Direct
Stock Option (Right To Buy) $218.4 2022-01-10 Common Stock (416.0) 416 Direct
Stock Option (Right To Buy) $27.05 2024-01-27 Common Stock (200000.0) 200000 Direct
Stock Option (Right To Buy) $51.0 2025-01-01 Common Stock (300000.0) 300000 Direct
Stock Option (Right To Buy) $30.86 2026-01-03 Common Stock (175000.0) 175000 Direct
Stock Option (Right To Buy) $18.01 2028-01-02 Common Stock (200000.0) 200000 Direct
Stock Option (Right To Buy) $33.02 2029-01-21 Common Stock (265000.0) 265000 Direct
Stock Option (Right To Buy) $33.02 2029-01-21 Common Stock (55000.0) 55000 Direct
Stock Option (Right To Buy) $51.16 2030-01-28 Common Stock (192500.0) 192500 Direct

Footnotes

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.12 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020.

F4: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: Currently exercisable.

F7: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

F8: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F9: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F10: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

F11: This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021.